1. Trastuzumab emtansine associated nodular regenerative hyperplasia: A case report and review of literature 
L.H. Prochaska, I. Damjanov, R.M. Ash, J.C. Olson, Q.J. Khan, P. Sharma 
Cancer Treatment and Research Communications 
Volume 5, Pages (January 2016)
DOI: /j.ctrc
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Fig. 1 CT imaging changes following T-DM1 initiation.
Cancer Treatment and Research Communications 2016 5, 26-30DOI: ( /j.ctrc )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Fig. 2
Liver function tests (A) and platelet levels (B) in relation to T-DM1 initiation and discontinuation.
Cancer Treatment and Research Communications 2016 5, 26-30DOI: ( /j.ctrc )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Fig. 3
Nodular regenerative hyperplasia (A) Hepatocytes form indistinct small nodules (arrows) compressing the surrounding cells. H&E×160. (B) Reticulin stain outlines the nodules and the compressed hepatocytes around them (×160). (C) Immunohistochemical stain with antibodies to cytokeratin that stains selectively the bile ducts and ductules. The lower lobule shows a ductal reaction around a portal tract missing the primary duct (bottom part of the figure). In the upper lobule there is a “blush-like” staining of periportal hepatocytes undergoing ductal metaplasia (×220). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Cancer Treatment and Research Communications 2016 5, 26-30DOI: ( /j.ctrc )
Copyright © 2015 Elsevier Ltd Terms and Conditions

5. Fig. 4 Treatment history timeline leading to development of NRH.
Cancer Treatment and Research Communications 2016 5, 26-30DOI: ( /j.ctrc )
Copyright © 2015 Elsevier Ltd Terms and Conditions